[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356156-105":59,"doc-detail-356156-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","deficiency-in-pole-exonuclease-causes-synthetic-lethality-in-highly-aneuploid-cancer-cells","Deficiency in POLE Exonuclease Causes Synthetic Lethality in Highly Aneuploid Cancer Cells","","Aneuploidy is a hallmark of cancer linked to drug resistance and poor outcomes, yet no therapies directly target highly aneuploid tumors. Using comprehensive genomic profiling of nearly half a million samples, the study identifies mutual exclusivity between POLE exonuclease domain mutations and high aneuploidy burden, confirmed with TCGA and CCLE data. Probabilistic modeling shows POLE exonuclease deficiency increases mutations that inactivate essential genes on chromosome arms with losses, producing synthetic lethality. Functional experiments indicate POLE exonuclease is required for viability in highly aneuploid cell lines but not in diploid cells. Selective POLE exonuclease inhibition emerges as a therapeutic strategy to target highly aneuploid cancers.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/deficiency-in-pole-exonuclease-causes-synthetic-lethality-in-highly-aneuploid-cancer-cells/356156/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/deficiency-in-pole-exonuclease-causes-synthetic-lethality-in-highly-aneuploid-cancer-cells/356156.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the key relationship between POLE exonuclease mutations and high aneuploidy burden?","Question",{"text":113,"@type":114},"Comprehensive genomic profiling reveals mutual exclusivity between POLE exonuclease domain mutations and high aneuploidy burden, independently validated using TCGA and CCLE datasets.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does POLE exonuclease deficiency lead to synthetic lethality in highly aneuploid cells?",{"text":118,"@type":114},"Probabilistic modeling indicates the mutation spectrum and quantity generated by POLE exonuclease deficiency increase the likelihood of inactivating essential genes on chromosome arms carrying losses, resulting in a synthetic lethal phenotype.",{"name":120,"@type":111,"acceptedAnswer":121},"Is POLE exonuclease essential only in highly aneuploid cancer cells?",{"text":122,"@type":114},"Functional experiments show POLE exonuclease activity is essential for the viability of highly aneuploid cancer cell lines, while it is dispensable in diploid cells.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356156,1790168074,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Deficiency in POLE Exonuclease Causes Synthetic Lethalityin Highly Aneuploid Cancer Cells  \nEun Jung Kim1, Dexter X. Jin2, Alejandro M. Chibly3, Kristel Dorighi4, Smruthy Sivakumar2, Jack Kamm3, Szymon Juszkiewicz5, Kevin Cabrera2, Rohit Reja3, Yangmeng Wang1,  \nRachel Nakagawa1, Minyi Shi6, Yuxin Liang6, Anwesha Dey5, Ethan S. Sokol2, Steven Gendreau1, and Meng He1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Aneuploidy is a hallmark of cancer and is associated with drug resistance and poor clinical outcomes across diverse cancer types. However, no therapies have been clinically established to target highly aneuploid tumors. By analyzing nearly half a million tumor samples subjected to comprehensive genomic profiling, we identified a striking mutual exclusivity between POLE exonuclease domain mutations and high aneuploidy burden. This observation was independently validated using data from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE). Probabilistic modeling revealed that the elevated quantity and unique spectrum of mutations induced by POLE exonuclease deficiency increase the likelihood of inactivating essential genes on\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | chromosome arms harboring losses, leading to a synthetic lethal phenotype in highly aneuploid cells. Functional experiments demonstrated that POLE exonuclease activity is essential for the viability of highly aneuploid cancer cell lines but dispensable in diploid cells. These findings suggest that selective inhibition of POLE exonuclease activity may represent a promising therapeutic strategy for targeting highly aneuploid tumors.\u003Cbr>Significance: An integrated approach using large-scale genomic analyses, probabilistic modeling and functional validation identified POLE exonuclease as a potential synthetic lethal target to overcome cancer aneuploidy. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nAneuploidy is a cellular state characterized by the acquisition of an abnormal number of chromosomes or chromosome arms (1). These chromosomal abnormalities are observed in more than 90% of solid tumors and approximately 50% of hematologic malignancies (2–4). Aneuploidy has been recognized as both a consequence and a driver of tumorigenesis (5–7). Although aneuploidy often reduces fitness in normal cells, cancer cells tolerate and even exploit chromosomal imbalances for increased fitness (8–10). Though the molecular mechanisms underpinning the initiation of aneuploidy is largely unknown, recent advances in single-cell genomics, karyotype-resolved sequencing, and functional genetics have illuminated the paradoxical  \n1Translational Medicine Oncology, Genentech Inc., South San Francisco, California. 2Foundation Medicine, Inc., Boston, Massachusetts. 3Computational Sciences Center of Excellence, Genentech Inc., South San Francisco, California. 4Department of Cell Therap","cbCaijkKRkjliAqs","https://ap.wps.com/l/cbCaijkKRkjliAqs","pdf",5176831,"English","# Introduction\n## Aneuploidy in cancer biology and clinical relevance\n## Molecular mechanisms and experimental advances","[{\"question\":\"What is the key relationship between POLE exonuclease mutations and high aneuploidy burden?\",\"answer\":\"Comprehensive genomic profiling reveals mutual exclusivity between POLE exonuclease domain mutations and high aneuploidy burden, independently validated using TCGA and CCLE datasets.\"},{\"question\":\"How does POLE exonuclease deficiency lead to synthetic lethality in highly aneuploid cells?\",\"answer\":\"Probabilistic modeling indicates the mutation spectrum and quantity generated by POLE exonuclease deficiency increase the likelihood of inactivating essential genes on chromosome arms carrying losses, resulting in a synthetic lethal phenotype.\"},{\"question\":\"Is POLE exonuclease essential only in highly aneuploid cancer cells?\",\"answer\":\"Functional experiments show POLE exonuclease activity is essential for the viability of highly aneuploid cancer cell lines, while it is dispensable in diploid cells.\"}]","Deficiency in POLE Exonuclease Causes Synthetic Lethality in Highly Aneuploid Cancer Cells | PDF",1790123697,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9fad5e53bbb2510b2d192a3dce1c1773.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bd105a297728897f62f8c61867c01e4.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd8827b54125020758d0032dd017532a.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4bcc0f24afab7f3f5f4f1322d19880b.webp",980,1311]